News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Euthymics Bioscience, Inc. Presents Data That Support Advancing EB-1020 into Clinical Trials for Adult ADHD



12/7/2011 6:35:32 AM

CAMBRIDGE, Mass. & WAIKOLOA, Hawaii--(BUSINESS WIRE)--Euthymics Bioscience, Inc. today announced that it has presented preclinical data demonstrating that EB-1020, a next-generation product candidate for adult attention deficit/hyperactivity disorder (ADHD), may be effective for treating ADHD without the burden of drug abuse liability. Euthymics’ EB-1020 is a novel triple reuptake inhibitor formulated for the treatment of ADHD as a norepinephrine and dopamine-preferring triple, with a small effect on serotonin. This combines the pharmacology of the brain chemicals most relevant for the treatment of ADHD in a single molecule—norepinephrine is believed to help with focus, while the increased dopamine is believed to improve problem solving capabilities, and may also lead to a faster speed-of-onset. EB-1020 is also active in animal models of depression, a common co-morbidity of ADHD. The data were presented at the 50th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Hawaii.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES